--- title: "AI That Bioprocess Teams Can Trust: Highlights from BioTalk Berlin" slug: ai-that-bioprocess-teams-can-trust-highlights-from-biotalk-berlin date: 2025-11-05 author: "Michael McCutchen" category: industry summary: "Recorded live at BioTalk Berlin on September 18, 2025 — featuring Michael McCutchen, Senior Product Manager at Invert. Scroll to the end to watch the full talk." url: https://invertbio.com/blog/ai-that-bioprocess-teams-can-trust-highlights-from-biotalk-berlin --- # AI That Bioprocess Teams Can Trust: Highlights from BioTalk Berlin ## The problem no one has time for (but everyone feels) Bioprocess data isn’t just fragmented — it’s fractured across ELNs, LIMS, historians, bioreactors, ÄKTAs, HPLCs, batch records, and CDMO file drops, each speaking a slightly different dialect of “pH” and “temperature.” The result: duplicate experiments, slow root-cause analysis, and painful tech transfer across scales and sites. Those costs are real: scientists burn cycles collating data instead of doing science; data quality and scope issues creep in; scale-up decisions get made with partial context. Meanwhile, the high-value opportunities (predictive models, ML-driven DoE, digital twins) stay theoretical because the data foundation isn’t ready. ## What “AI for bioprocess” actually requires At Invert, we start with a simple conviction: all bioprocess data should be accessible in a single, **batch-centric** system. That means ingesting from upstream and downstream equipment and systems, then making that data **unit-aware, metric-managed, and batch-aware**, with calculated features that reflect how bioprocess scientists really analyze runs (e.g., totals vs. instantaneous rates). This isn’t another generic BI layer. It’s a **trusted, AI-ready data foundation** with a native intelligence layer on top — live visualization, analytics built for USP/DSP, and a transparent AI interface — so teams can explore, compare, and decide without hand-stitching time series in Excel. Strong POV: Data alone is not enough. **Intelligence built on trusted data** is what drives faster, better decisions. ## Why “just slap an LLM on the database” fails Yes, modern language models are powerful. But when you point a stock LLM at raw bioprocess data, it stumbles on the things that matter most: **sequential, high-frequency time series** and **process optimization** questions. In our internal evals, a naïve approach produces sporadic “okay” answers on general reasoning — and near-zero capability on online data analysis. In other words: not production-ready. Even as LLMs improve generation to generation, that gap doesn’t magically close. You see uplift in general reasoning, but **no reliable trend on time-series comprehension** or optimization unless you add domain-specific scaffolding. ## The Invert approach: prompts, context, tools — and proof To make AI bioprocess-ready, we engineer around the model: - **Prompt engineering** to calibrate scientific reasoning (speculate where appropriate, avoid flights of fancy). - **Context engineering** to feed the right, batch-centric data at the right time. - **Tools/agents** that perform the domain work (e.g., time-series stats, chromatography overlays, growth-rate calculations) instead of hoping the base model “figures it out.” Then we do what scientists expect: **measure it**. ### Evals: assays for AI We use standardized prompts and auto-grading rubrics (0–1 scale) across four categories that map to real bioprocess work: 1. **General Reasoning** – find and interact with data 2. **Investigation** – pattern recognition & causality for root cause 3. **Online Data Analysis** – calculations and conclusions from time-series data 4. **Process Optimization** – prediction and next-best-action recommendations With Invert’s domain prompts, context, and tools, performance increases **immediately across all four** — including the historically tough **online data analysis** — and in several tasks our answers **saturate the scale (hit 1.0)**, forcing us to expand dynamic range with harder questions. That’s the standard you should demand before letting AI inform real decisions. ## From question to answer — without the swivel-chair During my live presentation, I showed prototypes of a chat interface that lets scientists ask natural-language questions (“What likely caused the titer drop in these runs?” “Recommend a scale-up DOE given these constraints.”) and receive answers backed by the right plots, stats, and context — not just text. The key: fast retrieval across **all** relevant runs and unit operations, with the guardrails to avoid apples-to-oranges comparisons. Because the platform is **batch-centric** and **unit-aware**, the AI can compare like with like, compute totals vs. rates, and pull DSP outcomes against upstream conditions — the pairwise links that matter for root cause and tech transfer — without hours of manual data wrangling. ## What this means for CMC leaders - **Accelerate answers.** Reduce deviation RCA from days to hours by traversing USP↔DSP data with context intact. - **Cut wasted runs.** Know what’s been tried, what worked, and what to change next; stop re-doing experiments due to missing context. - **De-risk scale-up and tech transfer.** Compare conditions and outputs across sites and scales with normalized, harmonized metrics. - **Make AI auditable.** Treat AI like a complex system you already know how to control: instrument it with evals, monitor drift, and hold it to measurable standards. Strong POV: **Delayed insights are wasted insights.** Live visibility and AI on a trusted foundation are now a competitive necessity. ## The takeaway - **Fragmented, unclean, and siloed data is holding back your AI-readiness.** - **A batch-centric, harmonized, unit-aware foundation** is the prerequisite. - **LLMs need domain scaffolding** (prompts, context, tools) to deliver. - **Evals are non-negotiable** — the assay that makes AI trustworthy in bioprocess.
### About Invert Invert is **Bioprocess AI Software** built by dual experts in bioprocess and technology. We unify, harmonize, and contextualize time-series data across instruments, sites, and CDMOs, then layer in real-time visualization, analytics, and a transparent AI interface — so teams cut wasted runs, lower cost and risk, and move therapies and sustainable products to market faster. Because waiting is no longer an option. **Interested in a deeper dive or a live demo?** Contact **Michael McCutchen** (Sr. Product Manager) at _michael@invertbio.com_ or **Hélène Panier** (Director of Strategic Partnerships, Europe) at _helene@invertbio.com_. _Speaker: Michael McCutchen, Senior Product Manager, Invert. Delivered at BioTalk Berlin (September 18, 2025)._